Q2 2026 T2Bmeets
Already know you want to attend?
RSVP here for T2Bmeet @ NY/NJ, T2Bmeet @ ASCO, T2Bmeet @ San Francisco, or T2Bmeet @ BIO / San Diego.
T2B Pro / Student members: get your promo code here
Register for T2Bmeet @ NY/NJ
T2B Pro or T2B Student members: get your promo code here
Look for an automated confirmation email and calendar invite within one business day from our event management platform, Luma. If you do not receive it, check your spam folder or contact us at [email protected].
Register for T2Bmeet @ ASCO
T2B Pro or T2B Student members: get your promo code here
Look for an automated confirmation email and calendar invite within one business day from our event management platform, Luma. If you do not receive it, check your spam folder or contact us at [email protected].
Boston
Register for our Biopharma Comms Forum and T2Bmeet @ Boston reception.
Register for T2Bmeet @ San Francisco
T2B Pro or T2B Student members: get your promo code here
Look for an automated confirmation email and calendar invite within one business day from our event management platform, Luma. If you do not receive it, check your spam folder or contact us at [email protected].
About our T2Bmeet @ SF host
Mirum Pharmaceuticals
​Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities.
​The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
​Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.
Register for T2Bmeet @ BIO / San Diego
T2B Pro or T2B Student members: get your promo code here
Look for an automated confirmation email and calendar invite within one business day from our event management platform, Luma. If you do not receive it, check your spam folder or contact us at [email protected].
About our T2Bmeet @ BIO / San Diego host
LifeSci Communications
​​LifeSci Communications is a healthcare communications agency built to tell the stories that matter most in biotech and life sciences. We partner with emerging and established innovators to translate complex science into clear, credible narratives that build confidence among investors, partners, physicians, regulators, and patients. As part of the LifeSci Partners ecosystem, we combine unique investor and market insights with deep scientific fluency and senior-level counsel to develop strategies that influence and inspire. Our integrated expertise delivers quality across earned media, corporate and product communications, social and digital strategy, and creative content – executed with agility and precision. We are headquartered in New York with teams in San Diego, Boston, and Madrid.